Its absence in biopsies from patients with amyloidosis, other GN, or healthy controls established DNAJB9 as the first biomarker for FGN, allowing differentiation from amyloidosis and other glomerular diseases [15,16]. This evidence concerns the gene DNAJB9 and ganglioneuroma.